Gilead Sciences, Inc. (GILD): BCG Matrix [June-2026 Updated]

This ready-made BCG Matrix Analysis of Gilead Sciences, Inc. gives you a concise, research-based portfolio view of the business, showing how key areas like Yeztugo, Biktarvy, HIV, Trodelvy, Livdelzi, and Veklury compare across growth, market share, and capital use. It highlights the company's $19.6 billion HIV franchise, Biktarvy's $13.4 billion sales and 70.0% U.S. share, 2024 revenue of $28.8 billion, the $32.0 billion U.S. investment plan through 2030, and the strategic split between Stars, Cash Cows, Question Marks, and Dogs-making it a practical study, research, and business-analysis aid.

Gilead Sciences, Inc. - BCG Matrix Analysis: Stars

The strongest Star in Gilead Sciences' portfolio is the lenacapavir prevention platform, commercialized as Yeztugo, because it combines a recent approval, high clinical differentiation, and clear scalability across multiple geographies. After the PURPOSE 2 study demonstrated superior efficacy, the FDA granted Breakthrough Therapy Designation on 2024-11-06, and the product launched on 2026-02-25. Positioned on top of Gilead's $19.6 billion HIV franchise and the 2024 Biktarvy base of $13.4 billion in sales, Yeztugo enters the market with an unusually powerful installed commercial foundation. Biktarvy still held 70.0% of the U.S. HIV market, which gives the prevention stack immediate access to prescribers, patients, and payer pathways already familiar with Gilead's HIV portfolio.

Yeztugo sits in the highest-upside HIV prevention position because it merges an approved launch with a superior Phase 3 readout and broad global licensing reach. Gilead reported 2024 HIV sales of $19.6 billion, representing about 68% of the company's $28.8 billion total revenue base. That concentration matters because a new prevention product can move the future mix disproportionately, especially when the existing core franchise is already large enough to support rapid commercialization. The 2025-12-31 workforce of more than 17,000 employees further strengthens the rollout capability across sales, medical affairs, manufacturing, and market access.

• Approved product status reduces launch risk versus earlier-stage pipeline assets.
• Superior efficacy data supports premium positioning in prevention.
• More than 120-country licensing broadens the addressable population.
• Large HIV franchise revenue creates funding capacity for expansion.
• Existing U.S. market leadership lowers adoption friction.

Capital allocation reinforces the Star classification. Gilead committed $32.0 billion through 2030 to U.S. research, AI-enabled labs, and manufacturing infrastructure, an unusually heavy level of investment for a single portfolio transition. Construction on the 182,000 sq ft Foster City technical development center began on 2025-09-05, showing that the capital plan is already being executed rather than merely announced. The Genesis Therapeutics collaboration announced on 2024-11-06 adds an AI discovery layer that can feed the prevention platform and future HIV innovation. Year-end 2024 cash, cash equivalents, and marketable debt securities of $10.0 billion provide liquidity to support this buildout without immediate balance sheet strain.

The scale of HIV prevention support also makes Yeztugo look like a classic Star rather than a speculative launch. Gilead's voluntary licensing network covers more than 120 countries, which is unusually broad for a newly launched product and gives the company a route into both high-income and access markets. The 2025-12-31 global workforce above 17,000 employees gives the organization the operational depth needed to support commercialization, supply chain execution, and medical education across multiple regions. The 2024 Q4 revenue of $7.6 billion and non-GAAP diluted EPS of $1.90 show that the core business is still generating meaningful cash while the new launch ramps.

• U.S. investment plan: $32.0 billion through 2030.
• Foster City center: 182,000 sq ft technical development facility.
• Liquidity: $10.0 billion in cash, cash equivalents, and marketable debt securities at year-end 2024.
• Operational scale: more than 17,000 employees at 2025-12-31.
• Commercial support: 2025 guidance of $28.2 billion to $28.6 billion in total product sales.

Access and launch readiness are especially important in defining the Star category for June 2026. The HIV prevention asset is supported by voluntary licensing in more than 120 countries, which allows Gilead to pursue scale beyond its domestic base. The company's HIV franchise remains the core cash-generating platform, with Biktarvy at $13.4 billion in 2024 sales and total HIV sales at $19.6 billion. That base helps fund the next wave of prevention adoption while keeping commercialization cost absorption manageable. The 2025 guidance range of $28.2 billion to $28.6 billion in total product sales indicates a stable revenue floor from which prevention growth can be expanded.

Core HIV franchise backing remains the anchor of the Star portfolio. The HIV business is Gilead's main cash-generating platform, and it supports new prevention launches with scale, physician trust, and payer familiarity. Biktarvy's $13.4 billion in 2024 sales illustrate how deep the franchise already is, while total HIV sales of $19.6 billion show the category's breadth. Oncology, by comparison, accounted for only 12.0% of total revenue by 2025-12-31, underscoring how concentrated Gilead's current business remains in HIV. This entrenched revenue base is what allows the company to invest aggressively in the prevention platform without compromising financial stability.

• HIV remains the dominant cash flow source for the company.
• Biktarvy provides a large physician and payer installed base.
• Prevention products can be layered onto existing treatment relationships.
• Commercial depth reduces the time needed to scale a new launch.
• Strong franchise economics support sustained Star investment behavior.

Gilead Sciences, Inc. - BCG Matrix Analysis: Cash Cows

Biktarvy is the clearest Cash Cow in Gilead Sciences' portfolio. In 2024, it generated $13.4 billion in sales and held a 70.0% share of the U.S. HIV market, giving it dominant scale in a mature category. That performance made it the largest product inside Gilead's $19.6 billion HIV franchise and a central driver of the company's $28.8 billion in full-year revenue. With the franchise continuing to produce strong cash flow and requiring comparatively limited reinvestment, Biktarvy fits the classic BCG Cash Cow profile.

The HIV franchise is Gilead's largest and most dependable segment. Full-year 2024 HIV sales of $19.6 billion exceeded oncology sales of $3.3 billion by nearly six times, underscoring how heavily the company still relies on this mature block. HIV contributed about 68% of total company revenue, showing that Gilead's cash profile remains concentrated in a highly successful but comparatively slow-growth franchise. This is exactly the kind of business unit that BCG would categorize as a Cash Cow: high share, high cash conversion, and low need for aggressive market expansion.

Gilead's quarterly performance also reinforces the Cash Cow profile. In Q3 2024, total revenue reached $7.5 billion, up 7.0% year over year, which shows the core machine was still expanding despite its mature base. A franchise that can continue growing at that pace while already generating more than $19 billion annually is a strong source of operating leverage. The scale of the HIV business provides the financial foundation for pipeline investment, commercial expansion, and shareholder returns.

• Biktarvy: $13.4 billion in 2024 sales
• U.S. HIV market share: 70.0%
• HIV franchise sales: $19.6 billion
• HIV share of company revenue: about 68%
• Q3 2024 company revenue: $7.5 billion
• Q3 2024 year-over-year growth: 7.0%
• Year-end cash and marketable securities: $10.0 billion

The global HIV commercial footprint strengthens the Cash Cow case further. Gilead's voluntary licensing agreements covered more than 120 countries by 2025-12-31, extending the reach of the franchise beyond the U.S. and creating durable international monetization channels. A broad commercial base like this reduces reliance on any single geography and allows the company to extract stable returns from a well-established therapeutic area. The 17,000-plus person workforce and the $32.0 billion U.S. investment plan are being supported by this cash-generating platform.

Capital allocation behavior is another sign of Cash Cow status. Gilead declared a $0.77 per share dividend on 2024-11-06 and paid it on 2024-12-30, while total dividends paid in 2024-Q3 reached $983.0 million. In 2024-Q4, the company repurchased $350.0 million of common stock, continuing a pattern of returning excess capital to shareholders. It also issued $3.5 billion of senior unsecured notes in 2024-Q4, showing confidence in using the balance sheet efficiently while preserving flexibility. These actions are typical of a mature business that generates more cash than it consumes.

The remainder of the HIV franchise after Biktarvy was roughly $6.2 billion in 2024, reflecting a long tail of older products that still contribute meaningfully to the cash pool. These residual assets do not appear to be the focus of a major growth story; rather, they serve as steady revenue contributors while newer programs take the strategic spotlight. Gilead's latest disclosures in 2026 are dominated by Yeztugo, BIC/LEN, and global licensing activity, not by a turnaround narrative for those legacy brands. That makes the residual HIV portfolio consistent with harvestable mature assets.

The maturity of the HIV business is also visible in the company's 2025 outlook. Gilead guided total product sales to $28.2 billion to $28.6 billion, signaling a stable but not hyper-growth base. A franchise that can sustain that level of revenue while remaining a leader in its category provides the cash that funds research, launches, and strategic expansion. The economic logic is straightforward: high-share, high-volume products like Biktarvy generate surplus cash, and that cash supports the broader enterprise.

• HIV franchise in 2024: $19.6 billion
• Residual HIV revenue after Biktarvy: roughly $6.2 billion
• 2025 product sales guidance: $28.2 billion to $28.6 billion
• Latest licensing footprint: more than 120 countries
• Workforce scale: 17,000-plus employees
• U.S. investment plan: $32.0 billion

Within the BCG framework, Gilead's HIV platform behaves like a mature Cash Cow because it combines dominant market share, strong profitability, and reliable cash flow with modest incremental growth requirements. Biktarvy provides the strongest single-product support, while the broader HIV franchise supplies the recurring revenue base that sustains dividends, buybacks, and pipeline funding. The scale and consistency of these cash flows make the HIV segment the financial center of the company.

Gilead Sciences, Inc. - BCG Matrix Analysis: Question Marks

Within Gilead Sciences' portfolio, the clearest Question Marks are the newer growth initiatives that require heavy capital, strong clinical execution, and rapid commercial conversion before they can justify their strategic cost. These assets sit in high-potential markets, but their current market share remains limited, making their future contribution uncertain.

Livdelzi is a prime example. The product received accelerated FDA approval on 2024-08-14 for primary biliary cholangitis, carrying a list price of $12,606 per 30-day supply. Gilead committed substantial capital to the asset, including the $4.3 billion CymaBay acquisition and a further $320.0 million payment on 2024-07-01 to buy out future royalties from Janssen. Even so, the approval was conditional on confirmatory Phase 3 trials to verify survival benefit in compensated liver cirrhosis, leaving the evidence base incomplete. Gilead positioned Livdelzi as an expansion into inflammation, but by June 2026 no market-share or revenue-scale disclosure had established commercial dominance.

Trodelvy occupies a similarly uncertain but commercially meaningful position. On 2025-05-31, the ASCENT-04 readout showed progression-free survival of 11.2 months versus 7.8 months for chemotherapy in first-line triple-negative breast cancer. That clinical improvement supports long-term relevance, yet the commercial picture remains mixed. Gilead recognized a $1.75 billion Trodelvy-related impairment in Q3 2024, indicating that prior expectations were reset lower. Oncology sales reached $3.3 billion in 2024 and accounted for 12.0% of total revenue by 2025-12-31, but the business still trails far behind HIV.

• ASCENT-04 delivered 11.2 months PFS versus 7.8 months with chemotherapy.
• Trodelvy carried a $1.75 billion impairment in Q3 2024.
• Oncology sales reached $3.3 billion in 2024.
• Oncology represented 12.0% of total revenue by 2025-12-31.
• Competitive pressure persisted from Enhertu and Datroway.

Trodelvy's market position is further complicated by competition. Enhertu has pressured the asset in HER2-low breast cancer, while Datroway introduced new pressure after 2025-06-01 in lung cancer. The combination of positive clinical data and contested commercialization makes Trodelvy a Question Mark rather than a Star. It has momentum, but not yet durable market leadership.

The bictegravir and lenacapavir combination, BIC/LEN, is another high-potential candidate. Two Phase 3 studies met their primary endpoints on 2025-12-15 and demonstrated non-inferiority to Biktarvy, which remains a major benchmark in HIV care. That benchmark is formidable because Biktarvy generated $13.4 billion in 2024 sales and held 70.0% of the U.S. HIV market. Yet BIC/LEN had no disclosed approved sales by June 2026, leaving its commercial share at zero in the public record.

Gilead's AI discovery platform also fits the Question Mark profile. The company's 2024-11-06 collaboration with Genesis Therapeutics to use the GEMS AI platform created strategic optionality, but no product revenue had been disclosed by June 2026. Gilead followed with a $32.0 billion U.S. investment plan on 2025-06-25 and began work on a 182,000 sq ft AI-enabled technical development center on 2025-09-05. These are substantial commitments, yet they remain infrastructure and capability investments rather than monetized businesses.

By 2025-12-31, Gilead's workforce exceeded 17,000, reinforcing the scale behind these initiatives. However, no market-share data were attached to the AI platform, and no approved products had been attributed to the collaboration in public disclosures. The absence of revenue, margin, or share proof keeps the platform in speculative territory.

• Genesis Therapeutics collaboration announced on 2024-11-06.
• $32.0 billion U.S. investment plan announced on 2025-06-25.
• 182,000 sq ft AI-enabled technical development center started on 2025-09-05.
• Workforce exceeded 17,000 by 2025-12-31.
• No disclosed product revenue by June 2026.

Oncology as a broader business line also remains a Question Mark. Gilead reported oncology sales of approximately 12.0% of total revenue by 2025-12-31, which signals diversification but not dominance. The segment's $3.3 billion in 2024 sales was still far below HIV's $19.6 billion, and the $1.75 billion impairment in 2024-Q3 showed that the portfolio had already been repriced downward. The 2025-05-31 TNBC data improved the clinical case, but the payoff remains uncertain because Enhertu and Datroway continue to shape the competitive field.

Gilead's latest product guidance of $28.2 billion to $28.6 billion reinforces that the company is still primarily powered by established HIV cash flows. The new initiatives are strategically important, but each still requires proof in revenue, share, or durable clinical differentiation. That is the defining feature of Gilead's Question Marks: strong intent, significant spending, and incomplete market validation.

Gilead Sciences, Inc. - BCG Matrix Analysis: Dogs

Veklury remains a legacy COVID-treatment asset in a post-pandemic market. The product generated approximately $1.8 billion of revenue in 2024, but Gilead's overall 2024 revenue was $28.8 billion and 2025 guidance ranged from $28.2 billion to $28.6 billion, which places Veklury far from being a primary growth driver. In the company's 2026 updates, management focus centered on Yeztugo, BIC/LEN, and Livdelzi rather than Veklury, reinforcing its limited strategic priority. With modest incremental growth visibility and declining relevance to the core portfolio, Veklury fits the Dog category in BCG terms.

Trodelvy in HER2-low breast cancer faces direct competitive pressure from Enhertu, which intensified after 2024-06-01. Gilead's $1.75 billion Trodelvy-related impairment in Q3 2024 signaled value erosion versus prior assumptions, and that accounting charge weighs heavily on the asset's BCG profile. Even after the 2025-05-31 ASCENT-04 win, oncology represented only 12.0% of total revenue at 2025-12-31, while HIV remained the dominant franchise at $19.6 billion in 2024. Against that backdrop, Trodelvy's share of the business is too small and too contested to qualify as a Star or even a strong Question Mark.

• 2024 oncology revenue: $3.3 billion
• 2024 HIV revenue: $19.6 billion
• Trodelvy impairment: $1.75 billion in Q3 2024
• Oncology share of total revenue: 12.0% at 2025-12-31
• Key competitive benchmark: Enhertu in HER2-low breast cancer

Trodelvy in lung cancer also sits in Dog territory. Datroway became the first FDA-approved TROP2 ADC for EGFR-mutated NSCLC on 2025-06-01, which directly lifted the competitive threshold in the category. Gilead had already disclosed pressure in lung cancer, and the earlier $1.75 billion impairment suggests the market is not rewarding the asset at prior expectations. With oncology still only 12.0% of revenue by 2025-12-31 and total oncology sales at just $3.3 billion in 2024, the franchise lacks the commercial scale needed to absorb repeated competitive shocks without margin strain.

The residual HIV tail also behaves like a Dog. After Biktarvy, the remaining HIV revenue in 2024 was about $6.2 billion, but Gilead's latest disclosures gave those older brands little standalone growth identity. The January 2025 PrEP patent settlement with U.S. DOJ/HHS protected future rights, yet the growth story in 2026 is centered on Yeztugo and BIC/LEN instead. Voluntary licensing in more than 120 countries supports access, but it also underscores that the newer prevention and treatment launches are the strategic engine.

• Residual HIV revenue after Biktarvy: about $6.2 billion
• PrEP patent settlement: January 2025 with U.S. DOJ/HHS
• Voluntary licensing footprint: more than 120 countries
• Primary growth focus in 2026: Yeztugo and BIC/LEN

In BCG terms, these assets share the same core traits: mature demand, limited upside, competitive pressure, and low strategic centrality. Veklury is a post-pandemic harvest asset, Trodelvy is constrained by stronger rivals in both breast and lung indications, and the older HIV tail is protected but no longer the center of growth planning. Together, they form the Dog portion of Gilead's portfolio.